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The Epstein–Barr virus (EBV) is associated with two major human epithelial malignancies, where it is likely to play a role
in the malignant phenotype: undifferentiated nasopharyngeal carcinoma (100% of cases) and gastric carcinomas (about 10%
of cases). We and others have obtained growth transformation of monkey kidney primary epithelial cells by transfection of
viral DNA, especially with the BARF1 gene of EBV (Wei et al., 1997). We now report that the same type of primary epithelial
cells can be growth-transformed using EBV particles derived from a nasopharyngeal carcinoma tumor line. Not only can
these EBV-infected cells grow over 100 passages, escaping senescence, in contrast to their noninfected counterparts, but
they can also survive and proliferate at very low cell density. Several subclones were characterized in terms of viral gene
expression. All these clones gave a similar pattern, with detection of EBNA1 and BARF1 proteins but absence of LMP1. CD21,
which is the main EBV receptor on B lymphocytes, was not expressed on parental monkey kidney epithelial cells nor on
EBV-infected cell clones. This model of epithelial cell transformation will be useful for a better investigation of EBV functions
critical for oncogenesis of epithelial cells. © 2001 Academic Press
B
v
B
t
s
pINTRODUCTION
The role of epithelial cells for EBV primoinfection and
persistence in healthy carriers is still unclear but it is
clear that both B-lymphocytes and epithelial cells can be
involved in EBV-associated oncogenesis. For example,
Burkitt’s lymphomas and posttransplant lymphomas are
derived from B-lymphocytes, while EBV-associated un-
differentiated nasopharyngeal carcinomas (NPC) are de-
rived from epithelial cells. Association of undifferentiated
NPC with EBV is constant regardless of patient origin. In
these tumors, all malignant epithelial cells contain the
EBV-genome (Klein et al., 1974; Teng et al., 1996; Zur
ausen et al., 1970) and express viral proteins like
EBNA1, LMP1, LMP2A, and BARF0 (Brooks et al., 1992;
Busson et al., 1992; Fahraeus et al., 1988; Gilligan et al.,
1991; Hitt et al., 1989; Young et al., 1988) as latent protein
and BARF1 (Sbih-Lammali et al., 1996a), DNAase (Sbih-
Lammali et al., 1996b), BZLF1 (Cochet et al., 1993), and
EA-D (Luka et al., 1988) as early antigens. Gastric carci-
noma is another epithelial malignancy which can be
associated with EBV, but with less consistency; approx-
imately 10% gastric carcinomas are EBV-positive (Osato
and Imai, 1996). Again, in the EBV-positive subgroup of
1 To whom correspondence and reprint requests should be ad-
ressed at Dr. T. Ooka, Laboratoire de Virologie Mole´culaire, IVMC,
NRS, Faculte´ de Me´decine R. Laennec, Rue G. Paradin, 69372 Lyon,
edex 08, France. Fax: (33) 04-78-74-96-68. E-mail: ooka@laennec.univ-
yon1.fr.
223gastric carcinomas, all malignant cells contain the EBV
genome and express viral latent proteins, except the
LMP1, EBNA2, and EBNA3 groups (Yoshima et al., 1997).
There are several experimental models to investigate
-lymphocyte infection and transformation by EBV. In
itro EBV infection can growth-transform not only human
-lymphocytes but also primate B-lymphocytes. In addi-
ion, intravenous injection of purified virions of the B95-8
train of EBV in tamarin induces a fast growing lym-
homa containing the EBV genome (Zhang et al., 1992)
and leading to animal death in about 3 weeks (Cleary et
al., 1985). This indicates that EBV is oncogenic in primate
B cells. In B cell lines transformed in vitro by EBV infec-
tion, about 11 viral genes (Kieff, 1996) are expressed and
contribute to the growth-transformed phenotype. Six of
them are known to be indispensable for this process
(Kieff, 1996).
In constrast, it is still difficult to investigate EBV infec-
tion and transformation of epithelial cells (Gan et al.,
1997; Sixbey et al., 1983). Several limiting factors should
be considered. For a long time, many reports have drawn
attention to the low rate of EBV penetration in epithelial
cells due to the absence or very low expression of the
CD21 molecule, which is the EBV membrane receptor on
human B-lymphocytes (Birkenbach et al., 1992). To over-
come this difficulty, the CD21 molecule has been artifi-
cially overexpressed or bypassed by various means, for
example, using the IgA transcytosis pathway (Knox et al.,
1996; Li et al., 1992; Gan et al., 1997). However, there are
clearly additional factors distinct from the low rate of
0042-6822/01 $35.00
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224 DANVE ET AL.virus penetration which hamper EBV infection in epithe-
lial cells. The epithelial cell environment seems to be
often unfavorable both to an efficient replicative cycle
and to the establishment of a stable mode of EBV latency.
Recently EBV conversion of established epithelial cell
lines has been achieved using a recombinant form of
EBV (Imai et al., 1998). This report has two major inno-
ative points. First, infection of epithelial cells was ob-
ained using cocultivation with Akata producer cells with
pparently no need for the CD21 receptor. Second, cells
etaining the EBV genome in a latent state of infection
ere positively selected using the neomycin resistance
ene carried by the recombinant virus. More recently an
pithelial cell line from stomach material was obtained
fter infection of a recombinant lymphotropic EBV parti-
le (Kawanishi et al., 1999). The established cell line did
ot express CD21 receptor.
Our aim was to obtain latent EBV infection of epithelial
ells associated with growth transformation, in other
ords, an experimental situation where EBV-infected ep-
thelial cells would be positively selected on the basis of
heir proliferative advantage. For this purpose, we chose
onkey kidney primary epithelial cells as recipients and
he NPC C17 tumor line as a source of natural EB virus
Busson et al., 1988). We here report that it was possible
ot only to infect these monkey primary cells with cell-
ree C17 virus preparation but also to obtain stably EBV-
nfected and growth-transformed cell clones. All trans-
ormed cells express EBNA1 and BARF1, in the absence
f detectable LMP1 or lytic proteins. BARF1 has onco-
enic activity in rodent fibroblasts (Wei and Ooka, 1989)
s well as a human B cell line (Wei et al., 1994), but also
n immortalizing activity in primary monkey epithelial
ells (Wei et al., 1997). Moreover the BARF1 gene was
T
Sequences and Localiz
Genes Primers 59–39
BARF1a MD2: GGGATCCAATGGAGGAGCAGGTGCTTATTGG
MD5: GGGATCCTTATGCCGCAGTTGGTGCGGGCTC
LMP-1b LMP1-S1: CTGAGGATGGAACACGACCTTGAGA
LMP1-AS1: TGAGCAGGATGAGGTCTAGG
LMP1-S2: ACAATGCCTGTCCGTGCAAA
LMP1-AS2: CTTCAGAAGAGACCTTCTCT
EBNA1c BamK EBNA1-A: CCCGCAGATGACCCAGGAAG
EBNA1-B: GGGTCCAGGGGCCATTCCAA
D21d CD21-S: GTTGTTCAGGTACCTTCCGC
CD21-AS: TAGGAAGTGCTGGACACTCG
Note. S, Sens; AS, Anti-sens.
a Wei et al., 1997.
b Brooks et al., 1992.
c Bhatia et al., 1996.
d Fujisaku et al., 1989.pecifically expressed in NPC biopsies (Decaussin et al.,
000). The BARF1 gene could therefore play an importantrole in epithelial oncogenesis. Our experimental model is
useful in understanding the oncogenic mechanism in-
duced by EBV.
RESULTS
Cell growth after infection by C17 tumor-derived EBV
Primary epithelial cells were subjected to infection by
EBV secreted by NPC cells derived from the C17 xeno-
graft. These cells were dispersed and maintained in
culture in vitro for two passages. Release of EBV virions
in culture medium was analyzed by PCR (amplification of
BARF1 sequence, see the primers used in Table 1) or by
electron microscopy analysis after sedimentation of the
virus. One mililiter of concentrated virus derived from 250
ml of culture medium collected at passage 2 was used
for infection (250-fold). For the detection of the EBV par-
ticle, DNA was extracted from 250-fold concentrated me-
dium. PCR was carried out to amplify an entire BARF1
sequence with 1 mg of DNA extracted from virus, B95-8,
nd IB4. Louckes DNA was used as a negative control. A
light amplified fragment was obtained from virus prep-
ration, while BARF1 negative Louckes DNA did not
how any band (Fig. 1). The concentration of virus deter-
ined by negative coloration on electron microscopy
as evaluated as about 1 3 105 particles/ml (data not
shown).
Infected and control uninfected primary cells were
seeded at a density of 0.6 3 106 cells in 10-cm petri
dishes. The primary Patas monkey kidney epithelial cells
are known to senesce after 10–16 passages in DMEM
supplemented with 10% FCS and EGF (Wei et al., 1997).
As expected, uninfected Patas stopped their growth be-
tween passages 12 and 16 (Fig. 2), while cells infected by
f Primers and Probes
5.8 genomic localization Size of amplified fragment DNA probes
165656–165576 382 bp C55
165996–166016
169456–169480 622 bp CB281
168858–168877
169081–169100 181 bp
169243–169262
109261–109280 330 bp
109571–109590
218–237 329 bp CD21
528–547ABLE 1
ation o
B9
GC17 EBV kept growing. EBV-infected Patas cells were
numbered at each passage. Major variations were ob-
c225EBV INFECTION OF PRIMARY EPITHELIAL CELLSserved in their rate of proliferation. A sharp increase in
cell proliferation was observed around passage 10, fol-
lowed by a marked slowdown until passage 14. A new
progressive increase in cell proliferation was noted from
passages 14 to 27. Beyond this period, the rate of prolif-
eration tended to stabilize at about three- to fourfold the
growth rate of uninfected Patas cells (1.2 3 106 cells for
uninfected cells and 3.6–4.8 3 106 for infected cells per
dish per week of culture). Recently (after 80 passages), a
new progressive increase in cell proliferation was again
observed (Fig. 2).
At the 20th, 35th, and 50th passages, EBV-infected
cells were examined for growth capacity at low cell
FIG. 1. Identification of the BARF1 gene in virus preparations. The
presence of the BARF1 sequence was searched in DNA extracted from
200-fold concentrated virus preparation. Akata, IB4, and C17 tumor
biopsies were used as EBV-positive controls and the Louckes cell line
as the EBV-negative control. After amplification of the BARF1 sequence,
the fragments were electrophoresed and transfered onto Hybond1
filters. The filters were hybridized with a probe, the C55 BARF1 cDNA
sequence. This corresponds to a 382-bp amplified fragment from the
BARF1 sequence.
FIG. 2. Growth curve of EBV-infected primary epithelial cells. Primary
number was counted every passage for 60 passages. One passage co
isolation by a dilution experiment (inserted in Fig. 1). (v----v) Infected cells;
urves of CD1, CD8, and CD9 in comparison with that of CD/C17.density for two reasons: this property is one of the clas-
sical criteria used to assess oncogenic transformation,
and practically this procedure is required to isolate
monoclonal sublines. Infected cells taken at the above-
mentioned passages were seeded in six-well plates at
the rate of 250, 500, or 1000 cells per well, in 3 ml of
culture medium (Wei et al., 1997). After 30 days, an
average of 3, 10, and 15 colonies were recovered in wells
seeded with 250, 500, and 1000 infected cells, respec-
tively. In contrast, no colonies were observed when un-
infected Patas cells (passage 2) were seeded at low
density. Ten clearly separated colonies were picked up
and designated subclones CD1 to CD10. In all sub-
clones, cell morphology was quite different from the
morphology of parental uninfected cells. While primary
Patas cells grew as disordered large cells (Fig. 3A), cells
from each subclone had two kinds of epithelial morphol-
ogy either with compact or with regular form (Fig. 3:
CD/C17, B; CD1, C; CD4, D).
The cell growth kinetics of the infected subclones was
similar to that of the parental infected cells (CD/C17)
except for the subclone CD1, which slightly reduced its
growth at the 50th passage (Fig. 2). Both parental and
subclone cells grow over 100 passages (corresponding
to a period of 24 months).
Identification of the viral genome in infected cells
The above-reported results had shown that EBV infec-
tion resulted in growth transformation of the primary
ey kidney epithelial cells were infected with C17-derived EBV. The cell
nds to 5 days. The cell numbers of subclones were also counted aftermonk
rrespo(f----f) uninfected cells. Three inserted curves correspond to growth
a
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226 DANVE ET AL.epithelial cells. To determine whether the EBV genome
was directly involved in this process, we first investi-
gated the presence of the EBV genome in transformed
cells. Three viral loci were investigated preferentially.
FIG. 3. Morphology of uninfected primary cells and EBV-infected
subclones. (A) Primary Patas cells; (B to D) EBV-infected cells: B,
CD/C17; C, CD1; D, CD4 subclone.
FIG. 4. Analysis of three EBV-encoded genes by polymerase chain
nalysis was carried out on DNA extracted from infected Patas cells. Th
nd 181 bp for the BARF1, EBNA1, and LMP1 sequences, respectively. E
ontrols. IB4, Akata, and C17 tumor cells were used as positive control
he filters were hybridized with the following probes: the C55 cDNA sequenc
MP1. (A) BARF1, (B) BKRF1 (EBNA1), and (C) BNLF1 (LMP1).These loci corresponded to the genes encoding
EBNA1(BKRF1), LMP1(BNLF1), and BARF1. Indeed,
EBNA1 is consistently expressed in all EBV-infected
cells, LMP1 is an oncogene indispensable for the growth
transformation of primary B cells, and BARF1 by itself
has the ability to growth-transform primary epithelial
cells. Viral genome fragments encoding EBNA1, LMP1,
and BARF1 were detected by PCR using appropriate
primer pairs (see Table I). The presence of this viral DNA
fragment was monitored, each five passages, until the
60th passage of the parental infected cells (CD/C17) (Fig.
4). All three genes were detected at all passages, but the
amounts of PCR products were quite variable.
Interestingly, we obtained a high intensity of amplified
fragment at the 2nd, 15th, 20th, 25th, and 30th passages
for all BARF1, LMP1, and EBNA1 genes. An optimum
peak of cell growth obtained at the 5th passage (see Fig.
2) showed very low intensity, while an optimum intensity
was observed at the 20th passage for all genes. The
amplified band at the 20th passage had the highest
intensity for three viral genes. The EBNA1 bands in Fig.
4B, lanes 5, 10, 35, and 45, which were difficult to visu-
alize, come probably from the low quantity of EBV ge-
on for 59 passages after infection with C17 tumor-derived EBV. PCR
were prepared every five passages. Amplified fragments are 382, 330,
ative Ramos and primary uninfected Patas cells were used as negative
amplification, DNA fragments were transfered onto Hybond N1 filters.reacti
e cells
BV-neg
s. Aftere for BARF1; a BamHI-K fragment for EBNA1; and a CB281 cosmid for
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227EBV INFECTION OF PRIMARY EPITHELIAL CELLSnome in these cultures (in particular at the 35th pas-
sage). It is quite possible that the loss of the EBV ge-
nome occurs during cell culture by a “hit end run”
mechanism (Galloway and McDougall, 1980). The EBV-
negative Ramos and uninfected Patas cells used here as
negative controls did not give any significant response
(Fig. 4, lanes Ramos and Patas).
The 10 clones derived from the infected Patas cells
(CD1 to CD10) at the 59th passage were subjected to
PCR analysis of the BARF1 and LMP1 genes. The paren-
tal CD/C17.1 cell line was processed in the same exper-
iments (Fig. 5). Interestingly, all 10 clones were positive
for each of the two genes. However, some subclones
(CD3 and CD5) gave relatively low amounts of PCR
products.
To confirm the presence of the EBV genome, Southern
blot was carried out on CD/C17 and CD8 (which are
positive to PCR) and P3HR-1 as well as IB4 (as positive
controls) DNA. DNAs digested with BamHI were electro-
phoresed, tranferred onto nylon filters, and hibridized
with a radiolabeled BamHI A fragment (11.8 kb). As illus-
trated in Fig. 6, P3HR-1 TK2 (containing 11 EBV genome
opies) gave a strong signal, while IB4 DNA (containing
or 2 copies) showed a weak signal. Signals from
D/C17 and CD8 were slightly higher than that of IB4. It
as very difficult to visualize a positive signal with other
D clones.
In order to know whether the EBV genome found in
atas suclones is the origin of C17 tumors, we amplified
small part of the LMP2 exon-1B region of CD/C17 and
17 original EBV genome using two primers: at positions
FIG. 5. Analysis of two EBV-encoded genes by PCR from DNA extrac
CR analysis was carried out on DNA extracted from immortalized Pata
81 bp (B) for the BARF1 and LMP1 sequences, respectively. EBV-negat
B4, Akata, and C17 tumor cells were used as positive controls. Amplifie
he following probes: the C55 cDNA sequence for BARF1; and a CB2867020–167039 as sense and 169913–169933 as anti-
ense for the EBV genome (Busson et al., 1995). Ampli-ication for CD/C17 was somehow difficult due to a lower
uantity of amplified fragment. Ten PCR reactions were
herefore put together to obtain a large enough quantity
f amplified fragment. The results confirmed that EBV
rom CD/C17 was of C17 origin, because we found two
utations specific to C17 EBV (in comparison with those
f the B95-8 strain): at 169740 (T3 A) and at 169764 (A3
) (data not shown) in the CD/C17 strain. This suggests
hat EBV present in CD subclones comes from C17
umor.
A 382-bp nucleotide sequence contained in the BARF1
RF was also PCR-amplified and sequenced from the
17 and B95 prototype EBV strain. No differences be-
ween the two EBV strains were found in this segment of
he viral genomes. The same sequence was also ampli-
ied from the CD1 clone and from parental EBV-infected
m a parental transformed Patas cell line and Patas-derived subclones.
lonal cells at the 59th passage. Amplified fragments are 382 bp (A) and
os and primary uninfected Patas cells were used as negative controls.
s were transfered onto Hybond1 filters. The filters were hybridized with
id for LMP1. CD/C17 is a parental transformed cell line.
FIG. 6. Identification of BamHI-A fragment in CD clones by Southern
blot. (A) CD8; (B) CD/C17; (C) IB4 (as a positive control); (D) P3HR-1-TK2ted fro
s subc
ive Ram(as a positive control); (E) Patas cells. The arrows indicate the size of
the BamHI-A fragment.
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228 DANVE ET AL.Patas cells. Again, no differences were found with the
C17 and B95 sequences (data not shown).
Expression of viral genes in growth-transformed
epithelial cells
Expression of the BARF1 protein was analyzed in each
EBV-carrying clone by immunoblot using an antipeptide
rabbit polyclonal antibody (Wei et al., 1997). TPA-induced
P3HR1 cells were used as a positive control. A charac-
teristic 31- to 33-kDa band was detected in all clones,
although with some variations in their intensity (Fig. 7A).
Interestingly, a protein extract derived from the C17
xenografted tumor was also strongly positive for the
BARF1 protein (Fig. 7A) (note that only 5 mg of the C17
rotein extract were loaded, whereas 50 mg of protein
FIG. 7. Detection of BARF1, EBNA1, and LMP1 proteins in subclones
protein encoded by the BARF1 ORF. Induced Raji and IB4 cell lines we
cells were used as positive controls for LMP1 protein and the human E
protein. Protein (50 mg) was electrophoresed in 12, 7.5, and 10% of ac
transfered onto a renforced nitrocellulose were incubated at 4°C with p
proteins were revealed by ECL reagent.as loaded for the clones). We also examined BARF1
rotein expression in Patas-derived cell lines by immu-
c
dofluorescence using a rabbit polyclonal antiserum pu-
ified by an affinity column. The results are presented in
ig. 8. Immunofluorescence was observed in the cyto-
lasm and nuclear periphery (Figs. 8B–8I), while no such
mmunofluorescence was detected in uninfected Patas
ells (Fig. 8A).
The presence of lytic proteins were also examined in
sing a monoclonal antibody against p135kDa (OT13B)
nd BZLF1 for early proteins and a monoclonal antibody
gainst gp350 for late protein. However, we never found
he expression of p135kDa and gp350 proteins in the
ransformed cell lines, while a very weak response of
ZLF1 was obtained with CD/C17 and CD1 subclones
data not shown).
EBNA1 protein expression was also analyzed in each
d P3HR-1 and C17 tumor cells were used as positive controls for p33
d as positive controls for EBNA1 protein. Induced Raji and C15 tumor
ative epithelial HaCaT cell line was used as negative control for LMP1
e for BARF1 (A), EBNA1 (B), and LMP1 (C), respectively. The proteins
III (for BARF1), OT1X-2 (for EBNA1), and S12 (for LMP1) antibodies. The. Induce
re use
BV-neg
rylamidlone (Fig. 7B). The size of the EBNA1 protein is variable
epending on the EBV strain. The EBNA1 bands ob-
with a p
and H)
229EBV INFECTION OF PRIMARY EPITHELIAL CELLStained for our positive controls, the Raji and IB4 cell lines,
were at the expected sizes, 65 and 75–78 kDa, respec-
tively (Fig. 7, lanes 1 and 2). We found a much larger size
(90–95 kDa) for the EBNA1 protein encoded by the C17
virus strain. This is consistent with observations made
on earlier passages of this nude mouse tumor (P. Bus-
son, personnal data). The EBNA1 protein was detected in
all clones, with a size similar to the size of the C17
EBNA1, around of 95 kDa, which was revealed with
monoclonal anti-EBNA1 and corresponds to that of the
C17 nude tumor (Fig. 7B, lane 4). The level of EBNA1
expression varied among the subclones. As already ob-
served for CD5 containing a very low EBV genome (Figs.
5A and 5B), the expression of EBNA1 was also low (Fig.
7B, lane 8).
To investigate EBNA1 expression at the single cell
level, we analyzed its expression by immunofluores-
cence on fixed cells using a serum from a North African
NPC patient (Fig. 9). Typical nuclear fluorescence was
observed in CD/CD17 (Fig. 9D), CD1 (Figs. 9B and 9C),
CD8 (Fig. 9E), and CD10 (Fig. 9F) clones, while the
parental patas cells did not show any positive immuno-
fluorescence (Fig. 9A). The level of EBNA1 expressing
cells was amost 100% for CD/C17 and CD10, while the
other clones expressed EBNA1 protein 90, 72, 64, 30,
FIG. 8. Expression of BARF1 protein and cytokeratins. Acetone-fixed
EBV-infected CD1 subclone (G–I) were examined for BARF1 expression
expression with two monoclonal antibodies, keratins 10 and 11 (B, E,and 21% for CD9, CD1, CD8, CD5, and CD4, respectively.
LMP1 expression was also analyzed in the EBV-in-fected clones (Fig. 7C). It has been previously shown that
LMP1 is not expressed in the C17 tumor (Clausse et al.,
1997). As expected, LMP1 was undetectable in the C17
tumor extract but it was readily detected in the Akata and
IB4 cell lines. None of the epithelial clones had LMP1
detectable by immunoblot. To achieve a greater sensi-
tivity in our detection and to rule out the possibility of
some antigenic polymorphism that would hamper recog-
nition by the S12 monoclonal antibody, we searched
LMP1 transcripts by RT–PCR using the primers indicated
in Table I. But LMP1 transcripts (amplification of a 460-bp
spliced sequence) were also undetectable in the C17
material and in all epithelial clones (Fig. 10), while Akata
and Raji cell lines gave a positive response.
Expression of CD21 in Patas cells
In order to know whether EBV could have used the
CD21 molecule to penetrate growth-transformed epithe-
lial cells, we intended to investigate the expression of
this receptor in Patas monkey cells. We first verified that
primers designed to amplify a segment of the human
CD21 gene were also able to amplify the homologous
segment in Patas monkey cells (Fujisaku et al., 1989).
This was the case, as shown in Fig. 11A. An expected
y Patas cells (A–C), EBV-infected parental CD/C17 cells (D–F), and an
olyclonal rabbit serum against BARF1 (A, D, and G) and for cytokeratin
, and specific for acidic and basic simple keratins (C, F, and I).primar329-bp fragment was amplified in all DNA samples of
human or monkey origin and these fragments hybridized
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230 DANVE ET AL.with an entire human CD21 sequence used as a probe
(Fig. 11B). In fact the nucleotide sequence analysis of
amplified fragment was identical in monkey (Patas and
B95-8) and human (Raji and Akata) B cells (data not
shown). Thus in the next step, CD21 gene transcription
was assessed by reverse PCR, using the same primer
pair, in control human cell lines (Raji, Akata, and 293) and
in epithelial monkey cells (noninfected primary cells,
infected parental cells, and clone CD1). A high level of
CD21 mRNA was detected in Raji and Akata cells and to
a lesser extent in 293 cells. In contrast, no CD21 mRNA
could be detected in Patas and Patas-derived cell lines.
Cytokeratin expression
To examine whether the immortalized Patas cell lines
were of epithelial origin, immunofluorescence with two
monoclonal antibodies specific for different kinds of cy-
FIG. 9. Immunofluorescence analysis of EBNA1 protein by ACIF. The
cells were grown on plastic chamber slides and fixed with methanol–
acetone (v/v). The slides were then incubated with a Tunisian NPC
serum (Tu 88) at a dilution of 1:200 and washed with PBS. After
treatment with C3, the slides were incubated with FITC-conjugated
anti-C3 antibody. (A) Uninfected Patas cells, (B) CD1, (C) CD1, (D) the
parental EBV-infected CD/C17 cell line, (E) CD8, and (F) CD9. Original
magnification, 3400 for A, C, D, E, F and 3200 for B.tokeratins was performed on Patas cells, EBV-infected
parental CD/C17, and a subclone, CD1 (Fig. 8). With
t
EK8-60 antibody raised against both cytokeratins 10 and
11, primary Patas cells and immortalizing cell lines were
positive (Figs. 8B, 8E, and 8H). With AE1/AE3 antibody
raised against both acidic and basic simple cytokeratins,
primary Patas cells and immortalizing Patas-derived cell
lines were also positive (Figs. 8C, 8F, and 8I). As in the
case of Patas cell line established by BARF1 transfection
(Wei et al., 1997), both cytokeratins were expressed in
cell lines immortalized with EBV. The detection of cyto-
keratins confirmed the epithelial origin of our immortal-
ized clones.
Tumorigenicity assays in nude mice
We examined whether EBV-infected patas clones are
tumorally transformed. The tumorigenicity of CD/C17,
CD10, CD9, CD8, CD3, and CD1 as well as Patas (as a
control cells) and HeLa cells (as a positive control) was
initially assayed by injection of 10 3 106 cells per animal
n nude mice. Tumor development was followed up for 4
eeks. HeLa cell-injected mice developed tumors as
arly as 1 week after injection, and their tumor size
ontinued to increase until 4 weeks, while none of the
D subclone-injected mice developed tumors (data not
hown).
DISCUSSION
There is strong evidence that EBV is the causative
gent of the process of growth transformation obtained
n monkey primary epithelial cells. This is a first demon-
tration that primary epithelial cells were immortalized
y a wild EBV. First, we did not observe, at any time,
pontaneous transformation in noninfected Patas cells,
hich consistently senesced before passage 16. Sec-
nd, all cell clones obtained by culture at low density
etained the EBV genome and expressed some viral
roteins. In addition, by immunofluorescence, it was pos-
ible to demonstrate that all cells of the transformed
lones or at least the vast majority of these cells were
BNA1 positive. This suggests that the maintenance of
he EBV genome is required for the persistence of the
ransformed phenotype. However, we observed a dimi-
ution of EBV genome content between the 20th and
0th passages. A very low amont of EBV genome was
onstantly found after the 40th passage. The subclones
ontained equal or inferior numbers of EBV genome
opies per cell to those of IB4 cells (in which only one
opy of the EBV genome was found). Similar contents of
BV genome were found in the subclones cultured for
ver 100 passages. The above observations suggest that
lmost all cells were infected by EBV at the 20th pas-
age, but some cells probably lose the EBV genome after
his period. In fact, when the expression of EBNA1 was
xamined in EBV-infected cells by immunofluorescence,hree of the subclones expressed almost 80–100%
BNA1 protein, while the other subclones had EBNA1
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231EBV INFECTION OF PRIMARY EPITHELIAL CELLSexpression between 20 and 70%. Possibly a “hit and run”
mechanism could occur in the latter, as observed in
HSV1 infection (Galloway and McDougall, 1980). Possi-
bly, the EBV genome is able to modify the host genome
specifically or may drive the primary cells to prolifirate,
allowing other mutations resulting the maintenance of
growth transformation after loss of EBV genome. This
kind of phenomenon was recently observed in continu-
ous growing Akata cells which lost the EBV genome
(Shimizu et al., 1994).
Despite the fact that Patas cells were obviously infect-
able by EBV, they were completely lacking CD21 expres-
sion at the messenger level. Recently, it has been shown
that several established human epithelial cell lines were
infectable by EBV, although they did not express detect-
able levels of CD21. However, in this system, cocultiva-
tion of epithelial target cells with EBV-producing Akata
cells was required to achieve infection of epithelial cells
(Imai et al., 1998). In contrast, in our experimental system,
EBV infection of epithelial cells was obtained and also in
the absence of CD21 expression, but with cell-free virus.
It will be important in future investigations to determine
which membrane molecules or molecular complexes
mediate EBV entry in Patas cells.
All the growth-transformed clones contained an
EBNA1 protein with a size identical to that of C17 EBNA1.
This was a confirmation in which the process of growth
FIG. 10. Detection of LMP1 transcription by RT–PCR in immortalized c
treated twice with DNase I to eliminate the contaminating DNA. After
using the primers indicated in Table 1. RNA without reverse transcrip
transferred onto Hybond1 filters and then hybridized with 32P-labeled CB
to a spliced sequence and a nonspliced genomic sequence, respectivtransformation resulted from the infection by an EBV
particle derived from the C17 NPC xenograft. Our ex-
f
mtended study showed that lymphocyte-derived EBV like
B95-8 or Akata was not able to immortalize Patas cells.
One may speculate that an EBV isolate derived from an
NPC tumor has better molecular equipment to penetrate
and stably transform epithelial cells.
It is probable that the products of several viral genes
acted in synergy to establish the growth-transformed
phenotype of EBV-infected Patas cells. Among them, the
BARF1 gene is likely to have played a major role. Not
only was the BARF1 protein consistently expressed in all
cell clones but we have previously shown that the BARF1
gene by itself can transform Patas epithelial cells (Wei et
al., 1997). However, transformed cells obtained by EBV
infection or by BARF1 gene transfection had distinct
charateristics. BARF1-transfected cells proliferated at a
higher speed, reaching about 40 3 106 cells after 1 week
of culture, starting from 0.6 3 106 per 10-cm plate,
hereas EBV-infected Patas cells reached only 3–4 3
06 under the same experimental conditions (Wei et al.,
997). To understand this paradox one should keep in
ind that in EBV-infected cells, BARF1 was expressed
nder its natural promoter instead of the retroviral LTR
romoter. It is conceivable that in this context, BARF1
ad different biological effects. Its transforming activity
ight be less marked and could require cooperation with
he products of other viral genes.
LMP1 was completely undetectable in growth-trans-
tal RNAs prepared from C17 tumor cells as well as the subclones were
ynthesis by reverse transcriptase, the LMP1 sequence was amplified
amed RT2) was used as a negative control. Amplified sequence was
mide containing LMP1 gene. Fragments of 460 and 622 bp correspondells. To
cDNA s
tase (normed Patas cells, at both the protein (immunoblot) and
essenger RNA levels (RT–PCR). This is not so surpris-
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232 DANVE ET AL.ing since LMP1 is expressed in only 30 to 50% of NPC
(Fahraeus et al., 1988; Young et al., 1988). For example,
MP1 is not expressed in the C17 NPC xenograft
Clausse et al., 1997), in transformed gastric epithelial
ells (Nishikawa et al., 1999), and in gastric carcinoma
iopsies (zur Hausen et al., 2000).
There are suggestions that EBV infection of trans-
ormed Patas cells is predominantly latent, with only a
inority of cells undergoing a productive cycle. VCA and
A proteins were not detected in a significant number of
ells. Thus these EBV-transformed primary epithelial
ells might become the prototype of a new type of EBV
atency, characterized by coexpression of EBNA1 and
ARF1 in the absence of LMP1 and another EBV nuclear
rotein, EBNA2 (data not shown).
We asked whether immortalized monkey epithelial
ells could induce a malignant transformation in nude
ice. However, additional experiments showed that im-
ortalized cell lines were not tumorigenic in nude mice.
nly Patas epithelial cells were immortalized. Even the
atas cells immortalized by BARF1 could not induce a
alignant transformation (Wei et al., 1997). Thus a sec-
nd cellular event will be necessary for inducing a ma-
ignant transformation in epithelial cells.
In any event, this model of EBV transformation of
rimary epithelial cells will likely become a major tool for
FIG. 11. Detection of the CD21 sequence and its transcriptional
expression in Patas cells. At first, the presence of the CD21 DNA
sequence was analyzed by PCR. Two human cell lines, Akata and 293,
as well as uninfected Patas and subclones, were subjected to analyses
by PCR. Using the primers (indicated in Table 1), 329 bp of fragment
was amplified. Second, the transcription of CD21 was analyzed with
RT–PCR on the above-mentionned cell lines, plus Raji cells. Amplified
sequences were transferred onto Hybond filters and hybridized with
the 32P-labeled CD21 sequence as a probe. (A) Amplification of CD21
NA sequence by PCR. (B) Amplification of cDNA synthesized from
NA by PCR. The left side (Patas to Raji) is without RT as negative
ontrols and the right side (Patas to Raji) with RT.better understanding of the transforming viral functions
nvolved in the pathogenesis of human EBV-associated
c
Marcinomas (nasopharyngeal carcinomas and gastric
arcinomas). This could be especially important for viral
unctions involved at early stages of oncogenesis. As we
id not succeed in immortalizing Patas cells with B-cell-
erived EBV, it will be interesting to further study whether
PC-derived EBV use specifically the gH/gL complex to
nter epithelial cells (Wang et al., 1998). One of our aims
s to simplify the process of Patas cell EBV transforma-
ion to provide a novel transformation assay that could be
sed in routine investigations of EBV isolates from vari-
us sources (saliva and other body fluids, supernatants
f primary cultures of malignant cells . . .). One way to
ake the assay shorter could be to seed infected cells at
ow density early after infection, for example, a few days
ostinfection. Such an experimental model will be useful
n qualitatively and quantitatively assessing the func-
ional consequences of strain polymorphism affecting
iral genes which are not expressed in most cells of
nvasive tumors (for example, the ZEBRA gene).
MATERIALS AND METHODS
ells and tumor material
Burkitt cell lines—EBV-carrying P3HR-1 and EBV-neg-
tive Louckes and BJAB cells—were maintained in RPMI
640 containing 10% fetal bovine serum with antibiotics
s previously described by Ooka et al. (1980). In order to
nduce the lytic cycle, P3HR-1 cells were treated with 50
g/ml of 13-O-tetradecanoylphorbol esther (TPA) and 2
M sodium butyrate (SB) (Ooka et al., 1983). The EBV-
egative human epithelial HaCaT cell line (a gift from Dr.
usenig, Institut fu¨r Biochemie, Heiderberg, Germany)
Boukamp et al., 1988) was maintained in Dulbecco’s
odified Eagle’s medium supplemented with 10% fetal
ovine serum.
We also used C15, C17, and C18 NPC tumor lines
outinely propagated as xenografts in nude mice (Busson
t al., 1988). C17-derived virus was obtained through a
tep of in vitro culture. A xenografted tumor collected at
assage 15 was minced in fragments smaller than 1
m3. Dispersed cells and fragments were maintained in
ulture in DMEM medium supplemented with EGF (0.01
mg/ml) in 10-cm petri dishes (Wei et al., 1997). After two
passages in vitro, 250 ml of culture medium was col-
lected and cleared from floating cells by a short centrif-
ugation at 1000 g. The supernatant was first filtered at 0.8
mm and then with 0.45 mm to eliminate cellular debrits.
ell-free virus was concentrated by a 2-h centrifugation
t 10,200 g. The pellet was resuspended in 1 ml (250-fold
oncentration) of RPMI 1640 and used to infect primary
idney epithelial cells derived from the monkey Erythro-
ebus patas (Patas cells purchased from Rhoˆne-
e´rieux, Lyon, France).
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233EBV INFECTION OF PRIMARY EPITHELIAL CELLSPreparation of cell extracts for immunoblotting
Cell pellets were resuspended in RIPA buffer contain-
ing 20 mM Tris–HCl (pH 7.5), 5 mM ethylendiaminotet-
raacetate (EDTA), 650 mM NaCl, 1% Triton, 0.5% desoxy-
cholate sodium, 1% SDS, 1 mM PMSF, and 1 mM pro-
ease inhibitor cocktail kit (ICN Biochemicals, CA).
ysates were frozen and thawed three times, sonicated
wice for 30 s with a Branson B-15 sonicator, and then
entrifuged at 105,000 g for 60 min in a Beckman 50 TI
otor. After the quantitation of protein, the supernatant
as frozen at 280°C until required.
ntibodies
The p33 BARF1 protein was detected with a rabbit
olyclonal antiserum (named peptide III) prepared
gainst a synthetic peptide (produced by Socie´te´ Bioat-
antic, Nantes, France) corresponding to a presumed
pitope (NGGVMKEKD, amino acids 172 to 180). This
ARF1 protein antiserum has been previously used for
mmunoblot and flow cytometry analysis at a 1:1000
ilution (Tanner et al., 1997; Wei et al., 1994). The EBNA1
rotein was detected with the OT1X-2 monoclonal anti-
ody (1:20,000 dilution for immunoblotting) (a gift from Dr.
. Middeldorp, Organon Teknika, The Netherlands). The
MP1 protein was detected with S12 monoclonal anti-
ody (1:5000 dilution for immunoblotting) (a gift from Dr.
horey-Lauwson, Tufts University, Boston, MA). For de-
ection of cytokeratins, the following monoclonal antibod-
es were used: K8-60 (Sigma) specific for cytokeratins 10
nd 11 or AE1/AE3 (Boehringer Mannheim) raised to
oth acidic and basic simple cytokeratins. For the detec-
ion of lytic proteins, a monoclonal OT13B antibody
gainst p135kDa (major DNA binding protein) (a gift from
r. J. Middeldorp, Organon Teknika, The Netherlands) for
arly protein and a monoclonal gp350 antibody for late
ntigen (a gift from Dr. E. Kieff, Harvard Medical School,
oston, MA) were used as previously described (De-
aussin et al., 1995).
mmunoblotting
Thirty to fifty milligrams of proteins quantitated by a
io–Rad protein assay (Bio–Rad Laboratories, Inc.) was
iluted with 1 vol of gel sample buffer (0.2% bromophenol
lue, 4% SDS, 200 mM DTT (dithiothreitol), 20% glycerol,
25 mM Tris–HCl, pH 6.8) and boiled for 5 min. Protein
amples were separated on polyacrylamide gels and
lotted onto reinforced nitrocellulose as previously de-
cribed (Cochet et al., 1993). Nonspecific protein binding
ites were blocked by overnight incubation of blotted
ilters in phosphate-buffered saline (PBS) with 0.1%
ween 20 and 5% dried skimmed milk or 5% commer-
ialized blocking agent (Blot-QuickBlocker, Chemiconnt., CA). The filters were subsequently incubated over-
ight at 4°C with specific antibodies or control preim-
aune sera or mouse IgG at the same dilution. Filters
ere washed and incubated for 1–2 h at room temper-
ture with peroxidase-labeled polyclonal anti-rabbit or
onoclonal anti-mouse secondary antibodies. The anti-
en–antibody complexes were then visualized using an
nhanced chemiluminescence system (ECL; Amersham)
s instructed by the manufacturer.
etection of BARF1, EBNA1, and LMP1 genes by
olymerase chain reaction (PCR)
PCR analysis was carried out in order to identify the
ARF1, EBNA1, and LMP1 genes in growth-transformed
atas cells. Experimental conditions were as previously
escribed (Wei et al., 1997, for BARF1, Bathia et al., 1996,
or EBNA1, and Books et al., 1992, for LMP1) with some
odifications. EBV DNA was amplified in a final reaction
ixture volume of 25 ml containing Taq polymerase
buffer (1 mM Tris–HCl, pH 8.3; 50 mM KCl), 2.5 mM
MgCl2, 20 mM each deoxyribonucleoside triphosphate,
250 nM each EBV primer, and 1 mg of DNA sample. The
engths of the PCR products were 382, 330, and 181 bp
or BARF1, EBNA1, and LMP1, respectively. After 10 min
ncubation at 95°C for denaturation of DNA, the mixture
ontaining 1.2 unit of Taq polymerase (Perkin–Elmer) was
added. Samples were subjected to 35 cycles. The dena-
turation step was 20 s at 94°C for all three amplified
genes. The annealing step was 30 s at 55°C for BARF1,
LMP1, and CD21, 30 s at 60°C for EBNA1. Elongation was
done1 min at 75°C for BARF1, LMP1, and CD21 and at
72°C for EBNA1. After the last cycle, samples were held
for 5 min at 75°C (BARF1, LMP1, and CD21) or 72°C
(EBNA1) and then cooled to 4°C. Twenty-five microliters
of the PCR mixture was analyzed on a 2% agarose gel,
transferred, and hybridized as described (Sbih-Lammali
et al., 1996). C55 cDNA and the BamHI-K and the EcoD-
het genomic fragments were used as probes for the
BARF1, EBNA1, and LMP1 genes products, respectively.
Detection of the EBV genome by Southern blot
To examine the presence of the EBV genome on
Southern blot, cellular DNA from CD/C17, CD8, and
P3HR-1 as well as IB4 was extracted in buffer (Tris–HCl,
10 mM, pH 7,4; EDTA, 50 mM; NaCl, 150 mM; Sarkosyl,
1% and proteinase K, 20 mg/ml). The mixture was incu-
bated first for 20 min at 55°C, followed by 1 h at 37°C,
and then extracted twice with 1 vol of phenol and chlo-
roform, before precipitation. For Southern blot analysis,
10 mg of cellular DNA was digested with the restriction
nzyme BamH1 and separated by electrophoresis in 1%
garose gels, followed by transfer to reinforced nitrocel-
ulose filters (Schleicher & Schuell). The probe (11.8-kb
amHI-A fragment) was labeled with random primers
6nd hybridization (1 3 10 cpm/ml of hybridization solu-
tion) was carried out for 15 h at 65°C.
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234 DANVE ET AL.Detection of CD21 and LMP1 transcripts by reverse
transcriptase–polymerase chain reaction (RT–PCR)
RNA was extracted as previously described (Wei et al.,
1994). To eliminate contaminating DNA, the RNA prepa-
ration was treated twice with 2 units of Escherichia coli
DNase-I/mg of RNA. After ethanol precipitation of RNA, 5
mg of total RNA was used for first strand cDNA synthesis
in a 40-ml reaction volume using oligo(dT)15 as primer.
everse transcription was done with Superscript reverse
ranscriptase according to the instructions of the manu-
acturer (GIBCO, BRL). Newly synthesized cDNA was
liquoted and stored at 220°C (Sbih-Lammali et al.,
996). PCR amplification was performed using 0.1 vol of
he first strand reaction mixture, 1.2 U of Taq polymerase
Perkin–Elmer), 2.5 mM MgCl2 and 250 nM each primer
on the CD21 RNA sequence, giving 329 bp of amplified
fragment in a 25-ml reaction mixture containing 20 mM
ach deoxyribonucleotide triphosphate and a standard
CR buffer. For each sample, a control tube without
everse transcriptase was added (deisgnated RT2). Am-
plifications were performed in a DNA thermal cycler
(Bio–Rad) as follows: denaturation at 94°C for 20 s;
annealing at 55°C for 30 s; and extension at 75°C for 1
min for 35 cycles. PCR mixtures were subsequently an-
alyzed by electrophoresis through a 1% agarose gel
followed by Southern transfer onto Hybond N1 nylon
membranes (Amersham). Detection of amplified CD21
and LMP1 sequences was achieved by hybridization to a
32P-labeled pZipCR2 vector (containing of 3.3-kb CR2
cDNA, a kind gift of Dr. F. Wang (Harvard Medical School)
for CD21 and EcoDhet for LMP1, using a random primer
DNA labeling kit (Stratagene). The filters were hybridized
as previously described (Wei et al., 1997).
Immunofluorescence
Standard immunofluorescence was performed for de-
tection of intracellular cytokeratins (Henle and Henle,
1966). The EBNA1 protein was identified at the single cell
level using the anticomplement immunofluorescence
(ACIF) reaction (Reedman and Klein, 1973). Epithelial
cells were grown on plastic chamber slides resistant to
acetone treatment, washed with PBS, fixed with cold
acetone/methanol (v/v) for 15 min, and dried. Fixed cells
were incubated for 45 min at 37°C with a 1:80 dilution of
TU 088, a serum from a Tunisian NPC patient, containing
a high titer of antibodies to EBNA1 and low titers of
antibodies to early (EA) and late (VCA) EBV antigens
(EBNA1, 1:1280; EA, 1:,10; and VCA, 1:40/80). Slides
ere further incubated 30 min with purified C3 (EBNA-
-negative human serum) at a 1:10 dilution. After three
ashes with PBS, they were treated with FITC-anti-C3
ntibodies (Sigma) at a 1:10 dilution for 30 min and
ashed three times with PBS and water.NA sequencing
The amplified 329 bp of CD21 and 382 bp of BARF1
CR products were sequenced by the ACT gene (Paris,
rance).
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